Subcutaneous bemiparin, a second-generation low-molecular-weight heparin, is an effective and well tolerated option for the prevention of venous thromboembolism (VTE) in surgical and medical patients, the treatment of established deep vein thrombosis (DVT), and the secondary prevention of VTE in at-risk patients following acute treatment of DVT. It is also effective in the prevention of clotting in the extracorporeal circuit during haemodialysis.